Literature DB >> 25420758

Antiproliferative activity of yatein isolated from Austrocedrus chilensis against murine myeloma cells: cytological studies and chemical investigations.

César Donoso-Fierro1, Antonio Tiezzi, Elisa Ovidi, Donatella Ceccarelli, Doriana Triggiani, Fabio Mastrogiovanni, Anna Rita Taddei, Claudia Pérez, José Becerra, Mario Silva, Daniele Passarella.   

Abstract

CONTEXT: Fitzroya cupressoides (Molina) I. M. Johnst. and Austrocedrus chilensis (D. Don) Pic.Serm. & Bizzarri are two Chilean Cupressaceae that are naturally resistant to biodegradation. Secondary metabolites from these species display a variety of biological activities.
OBJECTIVE: To evaluate the antiproliferative activity of two lignans, a diterpene and a flavonol isolated from A. chilensis and F. cupressoides, to elucidate their cytological effects on P3X murine myeloma cells.
MATERIALS AND METHODS: The antiproliferative activity of yatein, isotaxiresinol, ferruginol, and isorhamnetin was evaluated in vitro using the MTT assay. The effect of yatein at the cellular level, due to its high antiproliferative activity was evaluated. P3X cells treated for 24 h with 12.5 and 25 µg/mL of yatein were also examined at the cytological level using immunofluorescence and scanning and transmission electron microscopy.
RESULTS: Yatein, a lignan isolated from A. chilensis, potentially inhibited P3X murine myeloma cell proliferation, resulting in approximately 75% cell death in response to a 25 µg/mL treatment with the lignan. P3X cells lost membrane integrity at the nuclear and cytoplasmic levels, including organelles, in response to yatein treatment (12.5 µg/mL), and we observed changes in the cytoplasmic organization and distribution of microtubules. The other compounds tested had low activity. DISCUSSION AND
CONCLUSIONS: Yatein is a lignan precursor of podophyllotoxin, a key agent in anticancer drugs. Due to its structural similarities to podophyllotoxin, yatein could have similar cytoplasmic target(s), such as the microtubular apparatus. These findings suggest that yatein may be of potential pharmacological interest and warrants further investigation in human cell lines.

Entities:  

Keywords:  Anticancer; MTT; P3X; cytotoxicity; diterpene; lignans; microtubules; secondary metabolites

Mesh:

Substances:

Year:  2014        PMID: 25420758     DOI: 10.3109/13880209.2014.922588

Source DB:  PubMed          Journal:  Pharm Biol        ISSN: 1388-0209            Impact factor:   3.503


  5 in total

Review 1.  Lignans: a versatile source of anticancer drugs.

Authors:  Minky Mukhija; Bhuwan Chandra Joshi; Partha Sarathi Bairy; Anurag Bhargava; Archana N Sah
Journal:  Beni Suef Univ J Basic Appl Sci       Date:  2022-06-04

2.  Antiproliferative Properties of Papaver rhoeas Ovule Extracts and Derived Fractions Tested on HL60 Leukemia Human Cells.

Authors:  Elisa Ovidi; Valentina Laghezza Masci; Stefania Garzoli; Gabriella Gambellini; Saran Vittoria Keita; Daniele Zago; Giovanni Turchetti; Lorenzo Modesti; Antonio Tiezzi
Journal:  Molecules       Date:  2020-04-17       Impact factor: 4.411

Review 3.  An Ethnopharmacological, Phytochemical and Pharmacological Review on Lignans from Mexican Bursera spp.

Authors:  Maria Carla Marcotullio; Massimo Curini; Judith X Becerra
Journal:  Molecules       Date:  2018-08-08       Impact factor: 4.411

4.  Apoptotic Effects on HL60 Human Leukaemia Cells Induced by Lavandin Essential Oil Treatment.

Authors:  Valentina Laghezza Masci; Elisa Ovidi; Anna Rita Taddei; Giovanni Turchetti; Antonio Tiezzi; Pierluigi Giacomello; Stefania Garzoli
Journal:  Molecules       Date:  2020-01-26       Impact factor: 4.411

5.  Antiangiogenic and antihepatocellular carcinoma activities of the Juniperus chinensis extract.

Authors:  Zong-Keng Kuo; Mei-Wei Lin; I-Huang Lu; Hsin-Jan Yao; Hsin-Chieh Wu; Chun-Chung Wang; Shyh-Horng Lin; Si-Yuan Wu; Tien-Soung Tong; Yi-Cheng Cheng; Jui-Hung Yen; Ching-Huai Ko; Shu-Jiau Chiou; I-Horng Pan; Hsiang-Wen Tseng
Journal:  BMC Complement Altern Med       Date:  2016-08-08       Impact factor: 3.659

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.